Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI

YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024


SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering in in vivo gene editing therapies, today announced participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin Miyako Kyoto in Kyoto, Japan.

TIDES Asia, a conference in Asia that brings together discovery, clinical, delivery and CMC/manufacturing experts developing therapeutics/vaccines using modalities of Oligonucleotides, Peptides, mRNA and Genome Editing. Attendees from US, Europe and Asia come together to share scientific strategies and common challenges to help accelerate new molecules to market.

YolTech Therapeutics' representatives will bring latest advancements in in vivo gene editing technology and innovative LNP deliver system during the conference. Sincerely invites partners, investors, and stakeholders to join the session at TIDES Asia 2024 to share views of our breakthroughs.

Details are as follows:

Date: Wednesday, March 20, 2024
Time: 1:30pm -2:00pm JST
Location: The Westin Miyako Kyoto - Higashiyama Ward, Kyoto, Japan
Track: Track 1

About YolTech
YolTech Therapeutics is a pioneering gene editing company dedicated to develop a robust gene editing medicines to treat patients with serious diseases, which has built leading high-throughput evolution platform and innovative LNP deliver system. It possesses strong capability of novel Cas and base editor discovery and exceptional in-house LNP production capacity for GMP manufactory, with independent intellectual property rights and core patent protection globally. It has created a pipeline with 10+ genetic medicines focusing on cardiovascular diseases, metabolic diseases, infectious diseases as well as more common and rare diseases. Clinical trial clearance has been received for its leading in vivo gene editing asset YOLT-201 in March 2024.

For more information, please visit: www.yoltx.com or follow YolTech on LinkedIn https://www.linkedin.com/company/yoltech-therapeutics/

CONTACT: Wei Lu, [email protected]

SOURCE YolTech Therapeutics


These press releases may also interest you

at 09:53
Product: Meat and vegetable products Issue: Food ? Microbial Contamination ? Listeria Distribution:AlbertaBritish ColumbiaPossibly other provinces and territories See the affected products and product photos for this recall   SOURCE Canadian Food...

at 05:54
Contributing to the advancement of genomics in Latin America, MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced the launch of its Customer Experience Center (CEC) in Brazil.  ...

at 00:00
Capital Ophthalmic, a leader in the ophthalmic industry with over four decades of expertise, is proud to announce the launch of their comprehensive Preventative Maintenance Programs. These new offerings underscore Capital Ophthalmic's commitment to...

27 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:AlbertaBritish ColumbiaPossibly other provinces and territories See the affected products and product photos for this recall SOURCE Canadian Food...

27 avr 2024
On April 27 and 28 at San Francisco's Brava Theatre, Chacruna Institute for Psychedelic Plant Medicines will host its unmissable spring conference: Psychedelic Culture. This year's theme is Cultivating Roots for Cultural Change. Registration is still...

27 avr 2024
Product: Gift Chocolate Issue: Food - Allergen - Milk; Food - Allergen - Soy Distribution: Ontario, Quebec See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)



News published on and distributed by: